A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.
Sarah P. Blagden(Churchill Hospital), Essam Ghazaly(Queen Mary University of London), Ajithkumar Sukumaran(Imperial College London), Chathunissa Gnanaranjan(Queen Mary University of London), Christopher McGuigan(University College Dublin), Mark R. Middleton(University of Oxford), Hani Gabra(Royal Children's Hospital)
Cited by 2
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589